Europe Early Toxicity Testing Market by Technique Type (In Vivo, In Vitro, and In Silico), by Application (Drug discovery, Chemical testing and Others) and End Users (Pharmaceuticals Industry, Food Industry, Chemicals Industry, Cosmetics Industry, and Others): Opportunity Analysis and Industry Forecast, 2018 - 2025
- ALL3138297
- 181 Pages
- April 2019
- Medical Devices
Toxicity is the degree of threat posed by a substance to the living organism, and toxicology is a branch of science that deals with measurement and further analysis of these chemical substances and their adverse effects on the body of an organism. The effects of chemical substances on the body are studied to choose a potential drug candidate during the development of newer molecules. Early toxicity testing is carried out at preclinical stages of a drug development process and is essential as toxicity serves as the major reason for the failure of potential drug candidates in the later stages of drug development leading to huge financial loss to companies. Moreover, companies perform early toxicity testing to comply with the government standards to market the drug. Early toxicity testing can be performed using different techniques such as in vivo, in vitro, and in silico. These techniques are employed to carry out different toxicity tests such as ocular toxicity, carcinogenicity, systemic toxicity, and others.
Major factors that drive the market growth are surge in the research and development activities and increase in stringency of regulatory authorities concerning public healthcare welfare. In addition, technological advancements in vitro techniques, rise in adoption of in vitro models in the Europe early toxicity testing industry and surge in adoption of early toxicity testing further boost the market growth. However, limitations associated with preclinical testing hamper the market growth. Furthermore, the technological advancements related to early toxicity testing provide lucrative opportunities for the market growth during the forecast period.
This report segments the Europe early toxicity testing market on the basis of technique, application, end users, and country to provide a detailed assessment of the market. Based on technique, the market is divided into in vivo, in vitro, and in silico. The market on the basis of in vitro is further divided into in vitro toxicity testing market by assays and in vitro toxicity testing market by toxicity endpoints. The in vitro toxicity testing market by assays is further segmented into enzyme toxicity assays, bacterial toxicity assays, cell-based ELISA & western blots, receptor binding assays, and other assays. The in vitro toxicity testing market by toxicity endpoints is further divided into dermal toxicity, systemic toxicity, carcinogenicity, ocular toxicity, skin sensitization and irritation, neurotoxicity, organ toxicity, and other toxicity endpoints. Based on country, the market is studied across different countries of Europe such as Germany, France, the UK, and rest of Europe.
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the Europe early toxicity testing market along with the current trends and future estimations to elucidate the imminent investment pockets.
A quantitative analysis from 2017 to 2025 is discussed to enable the stakeholders to capitalize on the prevailing market opportunities.
In-depth analysis of early toxicity testing techniques such as in vivo, in vitro, and in silico is carried out in the report.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the European market.
KEY MARKET SEGMENTS
• By Technique
o In Vivo
o In Vitro
In Vitro Toxicity Testing Market by Assays
• Enzyme Toxicity Assays
• Bacterial Toxicity Assays
• Cell-Based ELISA and Western Blots
• Tissue Culture Assays
• Receptor Binding Assays
• Other Assays
In Vitro Toxicity Testing Market by Toxicity Endpoints
• Dermal Toxicity
• Systemic Toxicity
• Carcinogenicity
• Ocular Toxicity
• Skin Sensitization and Irritation
• Genotoxicity
• Neurotoxicity
• Organ Toxicity
• Other Toxicity Endpoints
o In Silico
• By Application
o Drug discovery
o Chemical testing
o Others
• By End User
o Pharmaceuticals Industry
o Food Industry
o Chemicals Industry
o Cosmetics Industry
o Other Industries
• By Country
o Germany
o France
o UK
o Rest of Europe
LIST OF KEY PLAYERS PROFILED IN THE REPORT (DEVICE PROVIDERS)
• Agilent Technologies, Inc.
• General Electric Company (GE Healthcare)
• Danaher Corporation (Beckman Coulter, Inc.)
• Evotec AG (Cyprotex)
• Bioanalytical Systems, Inc.
• Bruker Corporation
• Thermo Fisher Scientific, Inc.
• PerkinElmer Inc.
• Enzo Biochem, Inc. (Enzo Clinical Labs, Inc.)
• The Jackson Laboratory
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
• Randox Toxicology
• Geneva Laboratories, Inc.
• Advanced Chemistry Development (ACD/Labs)
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market Definition and Scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies, 2017
3.3. Top player positioning, 2017
3.4. Porter’s five forces analysis
3.5. Government Regulations
3.6. Market Dynamics
3.6.1. Drivers
3.6.1.1. Surge in research and development activities in healthcare
3.6.1.2. Rise in adoption of vitro model
3.6.1.3. Increase in stringency of regulatory authorities concerning public healthcare welfare
3.6.1.4. Surge in adoption of early toxicity testing
3.6.2. Restraints
3.6.2.1. Limitations of preclinical testing
3.6.3. Opportunities
3.6.3.1. Technological advancement in the field of early toxicity testing
3.6.4. Impact Analyses
CHAPTER 4: EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
4.1. Overview
4.1.1. Market size and forecast
4.2. In Vivo
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by country
4.3. In Vitro
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by country
4.3.3. In Vitro Early Toxicity Testing Market, By Assay
4.3.3.1. Enzyme toxicity assays
4.3.3.1.1. Market size and forecast
4.3.3.2. Bacterial toxicity assays
4.3.3.2.1.1. Market size and forecast
4.3.3.3. Cell-Based ELISA and Western Blots
4.3.3.3.1.1. Market size and forecast
4.3.3.4. Tissues Culture Assays
4.3.3.4.1.1. Market size and forecast
4.3.3.5. Receptor Binding Assays
4.3.3.5.1.1. Market size and forecast
4.3.3.6. Other Assays
4.3.3.6.1.1. Market size and forecast
4.3.4. In Vitro Early Toxicity Testing Market, By Toxicity End-Points
4.3.4.1. Dermal Toxicity
4.3.4.1.1.1. Market size and forecast
4.3.4.1.1.2. Market size and forecast, by end user
4.3.4.2. Systemic toxicity
4.3.4.2.1.1. Market size and forecast
4.3.4.2.1.2. Market size and forecast, by end user
4.3.4.3. Carcinogenicity
4.3.4.3.1.1. Market size and forecast
4.3.4.4. Ocular toxicity
4.3.4.4.1.1. Market size and forecast
4.3.4.4.1.2. Market size and forecast, by end user
4.3.4.5. Skin sensitization and irritation
4.3.4.5.1.1. Market size and forecast
4.3.4.6. Genotoxicity
4.3.4.6.1.1. Market size and forecast
4.3.4.7. Neurotoxicity
4.3.4.7.1.1. Market size and forecast
4.3.4.8. Organ toxicity
4.3.4.8.1.1. Market size and forecast
4.3.4.9. Other toxicity endpoints
4.3.4.9.1.1. Market size and forecast
4.4. In Silico
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by country
CHAPTER 5: EUROPE EARLY TOXICITY TESTING MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Medical
5.2.1. Market size and forecast, by type
5.2.1.1. Examination
5.2.1.1.1. Market size and forecast
5.2.1.2. Surgical
5.2.1.2.1. Market size and forecast
5.2.2. Market size and forecast, by country
5.3. Non-Medical
5.3.1. Market size and forecast, by type
5.3.1.1. Food services
5.3.1.1.1. Market size and forecast
5.3.1.2. Clean Room
5.3.1.2.1. Market size and forecast
5.3.1.3. Industrial
5.3.1.3.1. Market size and forecast
5.3.2. Market size and forecast, by country
CHAPTER 6: EUROPE EARLY TOXICITY TESTING MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Pharmaceutical Industry
6.2.1. Market size and forecast, by country
6.3. Diagnostics Industry
6.3.1. Market size and forecast, by country
6.4. Food Industry
6.4.1. Market size and forecast, by country
6.5. Chemicals Industry
6.5.1. Market size and forecast, by country
6.6. Cosmetic Industry
6.6.1. Market size and forecast, by country
6.7. Other Industries
6.7.1. Market size and forecast, by country
CHAPTER 7: EUROPE EARLY TOXICITY TESTING MARKET, BY COUNTRY
7.1. Overview
7.1.1. Key market trends, growth factors, and opportunities
7.1.2. Market size and forecast, by country
7.1.2.1. Germany
7.1.2.1.1. Germany market size and forecast, by technique
7.1.2.1.2. Germany market size and forecast, by application
7.1.2.1.3. Germany market size and forecast, by end user
7.1.2.2. France
7.1.2.2.1. France market size and forecast, by technique
7.1.2.2.2. France market size and forecast, by application
7.1.2.2.3. France market size and forecast, by end user
7.1.2.3. UK
7.1.2.3.1. UK market size and forecast, by technique
7.1.2.3.2. UK market size and forecast, by application
7.1.2.3.3. UK market size and forecast, by end user
7.1.2.4. Rest of Europe
7.1.2.4.1. Rest of Europe market size and forecast, by technique
7.1.2.4.2. Rest of Europe market size and forecast, by application
7.1.2.4.3. Rest of Europe market size and forecast, by end user
7.1.3. Market size and forecast, by technique
7.1.4. Market volume and forecast, by application
7.1.5. Market volume and forecast, by end user
CHAPTER 8: COMPANY PROFILES, KEY MANUFACTURERS
8.1. Agilent Technologies, Inc.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product type Portfolio
8.1.5. Business performance
8.2. General Electric Company (GE Healthcare)
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.3. Danaher Corporation (Beckman Coulter, Inc.)
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product type portfolio
8.3.5. Business performance
8.4. Evotec AG (Cyprotex)
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.5. Bioanalytical Systems, Inc.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.6. BRUKER CORPORATION
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.7. PerkinElmer Inc.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product Portfolio
8.7.5. Business performance
8.8. Enzo Biochem, Inc. (Enzo Clinical Labs, Inc.)
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product Portfolio
8.8.5. Business performance
8.9. The Jackson Laboratory
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Product Portfolio
8.9.4. Business performance
8.10. Thermo Fisher Scientific, Inc.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product Portfolio
8.10.5. BUSINESS PERFORMANCE
TABLE 01. EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2017–2025 ($MILLION)
TABLE 02. IN VIVO EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 03. IN VITRO EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 04. IN VITRO EARLY TOXICITY TESTING MARKET, BY ASSAYS, 2017–2025 ($MILLION)
TABLE 05. IN VITRO EARLY TOXICITY TESTING MARKET, BY ASSAYS, 2017–2025 ($MILLION)
TABLE 06. DERMAL TOXICITY MARKET, BY END USER, 2017–2025 ($MILLION)
TABLE 07. SYSTEMIC TOXICITY MARKET, BY END USER, 2017–2025 ($MILLION)
TABLE 08. OCULAR TOXICITY MARKET, BY END USER, 2017–2025 ($MILLION)
TABLE 09. IN SILICO EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 10. EUROPE EARLY TOXICITY TESTING MARKET, BY APPLICATIONS, 2017–2025 ($MILLION)
TABLE 11. EUROPE EARLY TOXICITY MEDICAL MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 12. EUROPE EARLY TOXICITY MEDICAL MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 13. EUROPE EARLY TOXICITY NON-MEDICAL MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 14. EUROPE EARLY TOXICITY NON-MEDICAL MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 15. EUROPE EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025 ($MILLION)
TABLE 16. EUROPE EARLY TOXICITY TESTING MARKET FOR PHARMACEUTICAL INDUSTRY, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 17. EARLY TOXICITY TESTING MARKET FOR DIAGNOSTICS INDUSTRY, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 18. EARLY TOXICITY TESTING MARKET FOR FOOD INDUSTRY, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 19. EARLY TOXICITY TESTING MARKET FOR CHEMICALS INDUSTRY, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 20. EARLY TOXICITY TESTING MARKET FOR COSMETIC INDUSTRY, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 21. EARLY TOXICITY TESTING MARKET FOR OTEHR INDUSTRIES, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 22. EUROPE EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 23. GERMANY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2017–2025 ($MILLION)
TABLE 24. GERMANY EARLY TOXICITY TESTING MARKET, BY APPLICATIONS, 2017–2025 ($MILLION)
TABLE 25. GERMANY EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025 ($MILLION)
TABLE 26. FRANCE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2017–2025 ($MILLION)
TABLE 27. FRANCE EARLY TOXICITY TESTING MARKET, BY APPLICATIONS, 2017–2025 ($MILLION)
TABLE 28. FRANCE EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025 ($MILLION)
TABLE 29. UK EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2017–2025 ($MILLION)
TABLE 30. UK EARLY TOXICITY TESTING MARKET, BY APPLICATIONS, 2017–2025 ($MILLION)
TABLE 31. UK EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025 ($MILLION)
TABLE 32. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2017–2025 ($MILLION)
TABLE 33. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY APPLICATIONS, 2017–2025 ($MILLION)
TABLE 34. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025 ($MILLION)
TABLE 35. EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2017–2025 ($MILLION)
TABLE 36. EUROPE EARLY TOXICITY TESTING MARKET, BY APPLICATION, 2017–2025 (UNITS)
TABLE 37. EUROPE EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025 (UNITS)
TABLE 38. AGILENT: COMPANY SNAPSHOT
TABLE 39. AGILENT: OPERATING SEGMENTS
TABLE 40. AGILENT: PRODUCT TYPE PORTFOLIO
TABLE 41. GE HEALTHCARE: COMPANY SNAPSHOT
TABLE 42. GE HEALTHCARE: OPERATING SEGMENTS
TABLE 43. GE HEALTHCARE: PRODUCT PORTFOLIO
TABLE 44. DANAHER: COMPANY SNAPSHOT
TABLE 45. DANAHER: OPERATING SEGMENTS
TABLE 46. DANAHER: PRODUCT TYPE PORTFOLIO
TABLE 47. EVOTEC: COMPANY SNAPSHOT
TABLE 48. EVOTEC: OPERATING SEGMENTS
TABLE 49. EVOTEC: PRODUCT PORTFOLIO
TABLE 50. BASI: COMPANY SNAPSHOT
TABLE 51. BASI: OPERATING SEGMENTS
TABLE 52. BASI: PRODUCT PORTFOLIO
TABLE 53. BRUKER: COMPANY SNAPSHOT
TABLE 54. BRUKER: OPERATING SEGMENTS
TABLE 55. BRUKER: PRODUCT PORTFOLIO
TABLE 56. PERKINELMER: COMPANY SNAPSHOT
TABLE 57. PERKINELMER: OPERATING SEGMENTS
TABLE 58. PERKINELMER: PRODUCT PORTFOLIO
TABLE 59. ENZO: COMPANY SNAPSHOT
TABLE 60. ENZO: OPERATING SEGMENTS
TABLE 61. ENZO: PRODUCT PORTFOLIO
TABLE 62. JAX: COMPANY SNAPSHOT
TABLE 63. JAX: PRODUCT PORTFOLIO
TABLE 64. THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
TABLE 65. THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS
TABLE 66. THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO
Similar Reports
Medical implants are permanent devices such as pacemakers or temporary devices such as fracture plates which are removed once their function is completed. These implants are made up of bone, tissue, skin, ceramics, metals, plastics, and other natural materials...
- Publish Date: August 21, 2016
- $5370
Ostomy is a surgery wherein an artificial opening, known as stoma, is created from the colon in the human body to eliminate body wastes such as urine, mucus, and stools, which are collected in artificial bags called ostomy drainage bags. These plastic/rub...
- Publish Date: December 1, 2016
- $5370
Laparoscopy is a minimally invasive procedure used to examine organs inside the abdomen or pelvic cavities by inserting a laparoscope through a small incision in the abdomen. A laparoscope comprises a long, thin tube with high-intensity light, and high-re...
- Publish Date: April 24, 2017
- $5370
